Screening for early prostate cancer detection may reduce the rate of newly diagnosed metastatic disease. In a published study researchers evaluated the incidence of a men receiving a diagnosis of metastatic prostate cancer at their initial prostate cancer diagnosis using data extracted from the Surveillance, Epidemiology, and End Results (SEER) Program database. Their analysis was [...]
Men of African origin are disproportionately affected by prostate cancer. You can read more Malecare's African American men and Prostate Cancer website, Twice As Many http://twiceasmany.org Three specific statistics tell the story. 1- In the United States, the incidence of prostate cancer is highest among men of African origin. 2- Prostate cancer mortality is highest among [...]
NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]
We have some good news, the United States Congress has passed the Omnibus spending package. The package will fund the U.S. Government through fiscal 2016. We should take note that this bill includes a $2 billion increase for the National Institute of Health (NIH), a 5% increase for the National Cancer Institute (NCI) and the [...]
My good friend and fellow advocate Mike Scott (Prostate Cancer Info Link) introduced me to a new web site produced by the University of Chicago called Cost of Care (www.CostofCare.org). The site is designed around the novel idea that the cost we must pay for our cancer care has become another negative side effect or [...]